EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Garadacimab for the long‐term prophylaxis of hereditary angioedema

Emel Aygören-Pürsün, Regina Treudler, Petra Staubach, Inmaculada Martinez Saguer, Thomas Linhoff, Markus Magerl

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026

DOI: 10.1111/ddg.70276 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Emel Aygören-Pürsün und 5 weiteren Autor:innen. Beteiligte Einrichtung: Goethe University Frankfurt, Department of Pediatrics, Frankfurt, Germany. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSL Behring, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments. The goal of HAE treatment as per guidelines is to achieve total disease control and to normalize patients’ lives. Factor XII (FXII), the principal initiator of the contact system, ultimately regulates the kallikrein–kinin system. Activated FXII (FXIIa) converts plasma prekallikrein to plasma kallikrein, which cleaves high‐molecular‐weight kininogen to produce the vasoactive peptide bradykinin. In HAE pathophysiology, kallikrein–kinin system dysregulation results in excessive bradykinin production. The anti‐FXIIa monoclonal antibody garadacimab is approved for long‐term prophylaxis against HAE attacks. In the pivotal phase III (VANGUARD) and ongoing phase III open‐label extension studies, garadacimab administered subcutaneously (2 × 200 mg loading dose followed by 200 mg once monthly) demonstrated durable efficacy with early onset of protection and a favorable long‐term safety profile. Based on this and earlier clinical data, garadacimab has the potential to bring patients closer to achieving the guideline‐recommended goals of disease control and normalization of life. Here, we provide an overview of the results from the garadacimab clinical development program.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryAntibodies, MonoclonalHumansTreatment OutcomeFactor XIIAntibodies, Monoclonal, HumanizedInjections, SubcutaneousEvidence-Based Medicine

Stichwörter der Autor:innen

FXIIagaradacimabhereditary angioedemalong‐term prophylaxis

Substanzen

Antibodies, MonoclonalFactor XIIAntibodies, Monoclonal, Humanizedgaradacimab

Autor:innen und Institutionen

  • Goethe University Frankfurt, Department of Pediatrics, Frankfurt, Germany.
  • Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Dermatology, University Medical Center, Mainz, Germany.
  • HZRM Haemophilia Centre Rhein Main, Frankfurt, Germany.
  • CSL Behring, Hattersheim, Germany.
  • Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, and Fraunhofer Institute for Translational Medicine and Pharmacolo…

Förderung

  • CSL Behring, LLC

Zitieren

APA

Aygören-Pürsün, E., Treudler, R., Staubach, P., Saguer, I. M., Linhoff, T., & Magerl, M. (2026). Garadacimab for the long‐term prophylaxis of hereditary angioedema. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.70276

Vancouver

Aygören-Pürsün E, Treudler R, Staubach P, Saguer IM, Linhoff T, Magerl M. Garadacimab for the long‐term prophylaxis of hereditary angioedema. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.70276

BibTeX
@article{AygrenPrsn2026,
  author = {Aygören-Pürsün, Emel and Treudler, Regina and Staubach, Petra and Saguer, Inmaculada Martinez and Linhoff, Thomas and Magerl, Markus},
  title = {Garadacimab for the long‐term prophylaxis of hereditary angioedema},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.70276}
}
Kostenlos starten →